ArticlePakistan journal of medical sciences2026
Assessment of clinical characteristics, treatment responses, relapses, and survival in patients with thrombotic thrombocytopenic purpura undergoing therapeutic plasma exchange: A single-center experience.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The present study evaluates the clinical characteristics, laboratory values, treatment responses, relapse rates, and survival outcomes in patients diagnosed with thrombotic thrombocytopenic purpura (TTP) undergoing therapeutic plasma exchange (TPE). Methodology: Included in this retrospective single-center study were 55 patients who underwent TPE with a diagnosis of TTP between 2012 to 2025. The study was conducted between October and December 2025 at Van Yuzuncu Yil University Medical Faculty Hospital. Demographic characteristics, clinical findings, laboratory results, administered therapies, complications, treatment responses, and survival data were retrieved from the hospital automation system and patient medical records. Results: The median age of the patients was 34 years, and 67.3% were female. Based on PLASMIC scores, 76.4% of the patients were classified as high risk, among whom 36.4% tested positive for an ADAMTS13 inhibitor (a disintegrin and metalloproteinase with a thrombospondin type-1 motif, member 13). The complete response rate to TPE was 75.5%, whereas the relapse rate was 23.6%, and among those who relapsed, 84.6% tested positive for the ADAMTS13 inhibitor. The median event-free survival (EFS) was 158 months, and the overall survival (OS) rate was 92.7%. The mean OS duration was determined to be 157.2 months. The median EFS was 64.8 months in those who tested positive for the ADAMTS13 inhibitor, and 158 months in those who tested negative. Conclusion: In the present study, TPE achieved high response and survival rates. High PLASMIC scores strengthen the clinical utility of the scoring system in the diagnosis of TTP. ADAMTS13 inhibitor positivity was a significant indicator of relapse risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.